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1. Introduction 
There is complex and ubiquitous interface between the probiotic and resident bacteria (human 
microbiota) at various mucosal sites and the mucosal immune system. The probiotic bacteria 
are normally exogenous and transient as the resident bacterial communities of the human 
body are relatively constant companions of the human body and the mucosal immune system. 
This interface may result in local and systemic immune responses thus contributing for the 
preservation of the biological individuality of the human macroorganism.  
2. Human microbiota  
The human microbiota is an aggregate of microorganisms that reside on the surface and in 
deep layers of skin, in the saliva and oral mucosa, in the conjunctiva, the urogenital, to some 
extend the respiratory and above all the gastrointestinal tract. They include mostly Bacteria, 
but also some Fungi and Archaea. All these body parts are offering a relatively stable habitat 
for the resident bacteria: constant nutrient influx, constant temperature, redox potential and 
humidity. The skin flora does not interact directly with the mucosal immune system so it 
would be excluded from the present book chapter.  
2.1. Oral microbiota  
The oral cavity shelters a very diverse, abundant and complex microbial community. Oral 
bacteria have developed mechanisms to sense their environment and evade or modify the 
host. Bacteria occupy the ecological niche provided by both the tooth surface and gingival 
epithelium. A varied microbial flora is found in the oral cavity, and Streptococcal anaerobes 
inhabit the gingival crevice. The oral flora is involved in dental caries and periodontal 
disease, which affect about 80 %. of the population in the Western world. Anaerobes in the 
oral flora are responsible for many of the brain, face, and lung infections that are frequently 
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manifested by abscess formation. Oral bacteria include Streptococci, Lactobacilli, Staphylococci, 
Corynebacteria and various anaerobes in particular Bacteroides. The oral cavity of the new-
born baby does not contain bacteria but rapidly becomes colonized with bacteria such as 
Streptococcus salivarius. With the appearance of the teeth during the first year colonization 
by Streptococcus mutans and Streptococcus sanguinis occurs as these organisms colonise the 
dental surface and gingiva. Other strains of streptococci adhere strongly to the gums and 
cheeks but not to the teeth. The gingival crevice area (supporting structures of the teeth) 
provides a habitat for a variety of anaerobic species. Bacteroides and Spirochetes colonize the 
mouth around puberty. However, a highly efficient innate host defense system constantly 
monitors the bacterial colonization and prevents bacterial invasion of human tissues. A 
dynamic equilibrium exists between dental plaque bacteria and the innate host defense 
system. [1, 2].  
2.2. Respiratory microbiota  
The nose, pharynx and trachea contain primarily those bacterial genera found in the normal 
oral cavity (for example, α-and β-hemolytic streptococci); however, anaerobes, Staphylococci, 
Neisseriae and Diphtheroids are also present. Potentially pathogenic organisms such as 
Haemophilus, Mycoplasmas and Pneumococci may also be found in the pharynx. Anaerobic 
organisms also are reported frequently. The upper respiratory tract is so often the site of 
initial colonization by pathogens (Neisseria meningitides, C. diphtheriae, Bordetella pertussis, 
etc.) and could be considered the first region of attack for such organisms. In contrast, the 
lower respiratory tract (small bronchi and alveoli) is usually sterile, because particles the 
size of bacteria do not readily reach it. If bacteria do reach these regions, they encounter host 
defense mechanisms, such as alveolar macrophages, that are not present in the pharynx [2]. 
2.3. Conjunctival microbiota  
The conjunctiva harbors few or no organisms. Haemophilus and Staphylococcus are among the 
genera most often detected [2].  
2.4. Urogenital microbiota  
The urogenital flora is comprised mostly by the bacteria in the anterior urethra and the 
genital tract in women. In the anterior urethra of humans, S. epidermidis, enterococci, and 
diphtheroids are found frequently; E. coli, Proteus, and Neisseria (nonpathogenic species) are 
reported occasionally (10-30 %). The type of bacterial flora found in the vagina depends on 
the age, pH, and hormonal levels of the host. Lactobacillus spp. predominate in female infants 
(vaginal pH, approx. 5) during the first month of life. Glycogen secretion seems to cease from 
about I month of age to puberty. During this time, diphtheroids, S. epidermidis, streptococci, 
and E. coli predominate at a higher pH (approximately pH 7). At puberty, glycogen secretion 
resumes, the pH drops, and women acquire an adult flora in which L. acidophilus, 
Corynebacteria, Peptostreptococci, Staphylococci, Streptococci and Bacteroides predominate. After 
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menopause, pH again rises, less glycogen is secreted, and the flora returns to that found in 
prepubescent females. Yeasts (Torulopsis and Candida) are occasionally found in the vagina 
(10-30 % of women); these sometimes increase and cause vaginitis [2].  
2.5. Intestinal microbiota  
The number of bacteria in the digestive system alone is at least as big as the number of the 
stars in our home galaxy – the Milky Way as it contains no less than 1011 stars [3], thus 
forming a specific bacterial microcosmos the human gut. The number of bacteria increases in 
a logarithmic progression along the digestive system: the stomach (101-103 colony-forming 
units per milliliter (cfu/ml)), duodenum (101-103 cfu/ml), distal small intestine (104-107 
cfu/ml) and above all the colon (1011-1012 cfu/ml). According to some authors the intestinal 
bacteria are forming the most densely populated ecosystem in the world [4]. The intestinal 
bacteria are really abundant when it comes to the various species and strains and their 
spatial distribution. The intestinal flora has a dynamic structure and is not isolated from the 
human host or the surrounding environment. There qualitative and quantitative variations 
in the gut flora depending on the diet, age, biotic and abiotic factors of the human 
environment, mucosal immune respose, presence or absence of organic disease of the host, 
intake of antibacterial medications, etc. The interface between the gut flora and the intestinal 
mucosal immune system is a perfect example for the interaction between the resident 
bacteria and the mucosal immune response. The gut flora is quite unique for each and every 
person and differs even in identical twins [5, 6]. The predominant bacterial genera and 
families inhabiting the human gut are presented on table 1 [4, 7-14]: 
 
 Facultative 
anaerobes 
Gram 
staining 
Obligate anaerobes Gram 
staining Location 
Duodenum and 
Jejunum  
Lactobacillus 
Streptococccus 
Enterobacteriaceae 
+ 
+ 
- 
Solitary Bacteroides - 
Ileum Lactobacillus 
Streptococccus 
Enterococcus 
Enterobacteriaceae 
+ 
+ 
+ 
- 
Bacteroides 
Clostridia 
Veillonella  
- 
+ 
- 
 
Colon Lactobacillus 
Streptococccus 
Enterococcus 
Enterobacteriaceae 
+ 
+ 
+ 
- 
Bacteroides  
Bacillus 
Clostridium 
Fusobacterium 
Peptostreptococcus 
Bifidobacterium 
Eubacterium  
Ruminococcus 
- 
+ 
+ 
- 
+ 
+ 
+ 
- 
Table 1. Predominant bacterial genera and families inhabiting the human intestine. 
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The intestinal flora may be divided to resident and transient. The resident bacteria can 
colonize and multiply successfully in the human gut for continuous periods of time as the 
transient microbial species can only do so for limited periods of time. The resident bacteria 
are able to adhere to specific molecules of the host or other adhesive bacterial species. Most 
of the transient bacteria are unable to do so or can only do it for a short time. The transient 
bacteria are usually ingested trough the mouth and belong to various genera and species 
[15].  
3. Probiotic bacteria  
The probiotic bacteria belong to the transient species as their presence in the human body is 
always a result of exogenous intake. There are numerous definitions for probiotics and they 
all correct in a way of their own. The concept for probiotics is constantly evolving, but 
essentially designates that they are “Living microorganisms which favorably influence the 
health of the host by improving the indigenous microflora”. This definition was given by R. 
Fuller back in 1989 [16] and is very distinct from the one of the World Health Organization 
given in the beginning of the 21st century – “Live microorganisms which when administered 
in adequate amounts confer a health benefit on the host” [17]. There are also many other 
definitions and they all speak of the “whats”, the “whos” and the “whens” but none speaks 
of the “hows”. So if one would wish to include the “hows” it may sound like “Living 
microorganisms which when administered in adequate amounts may change the balance 
and keep the human body move in the right direction…”. It does not say “favorable” as 
probiotics also have side effects and still it does not speak enough of “hows” so it can’t 
really become the universal definition for probiotics. The intake of probiotic bacteria can be 
reviewed not only from a therapeutic and immunological angle but also unraveled throught 
the prism of ecology and cognitive philosophy.  
The probiotic bacteria exert the unique quality to change the balance in a balanced way. 
They way they work is quite complex and fall pretty much into the witty remark of Albert 
Einstein “Life is like riding a bicycle – in order to keep your balance, you must keep 
moving” [18]. Indeed probiotic bacteria are alive and keep moving so as the human body. So 
when we want to understand probiotics everything comes to the balance between the outer 
and the inner cosmos of humans mediated by their mucosal surfaces. 
The majority of commercially available probiotic bacteria belong to the genera Lactobacillus and 
Bifidobacterium but also strains of E. coli, Streptococcus, Enterococcus and even Bacillus, Oxalobacter, 
etc. Some yeasts are also being used as probiotics – Saccharomyces, etc. All commercially 
available probiotic bacteria must exert 5 crucial technological and clinical properties (fig. 1). 
All these properties are equally important but the positive effect is by all means the most 
significant one: 
 Origin: bacteria descending from the human gastrointestinal tract (GIT) (preferably); 
 Safety: probiotic bacteria should be non-pathogenic and sensitive to the most commonly 
used antibiotics; 
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Figure 1. Main technological and clinical properties of the probiotic bacteria. 
 Resistance: the bacterial strains should be able to survive the action of the stomach acid, 
the bile acids and the protease enzymes; 
 Viability: these bacteria must survive the production process, proliferate in the small 
and/or large intestine, adhere to the gut epithelium and even colonize the small 
intestine and/or the colon for a finite time; 
 Positive effect: their intake should be beneficial for health of the human macroorganism.  
There is still conflicting evidence for the clinical efficacy of probiotic bacteria but yet they 
have been proven to be effective in infectious and antibiotic associated diarrhea [19, 20], 
urogenital infections [21, 22], immunologically mediated diseases such as inflammatory 
bowel disease (IBD) [23, 24] and atopic disease [25, 26], etc. Probiotic bacteria are being 
applied at various mucosal sites – orally, vaginally, as eye-drops, nasal sprays, etc. All 
mucosal sites are all connected in 3 different ways: anatomically, embryologically and most 
of all functionally.  
4. Mucosal ecology  
The intestinal flora is a specific blend of microorganisms, which have evolved and 
developed together with the macroorganism. These bacterial communities are highly 
variable and unique for all living persons. This is a result of time-limited migration of 
bacteria between humans in combination with their active interaction with the mucosal 
immune system, dietary and some genetic factors [27]. Human mucosal sites are classical 
habitats – they are normally populated by resident microorganisms. The human microbiota 
together with the mucosal surfaces of the human body form complex and dynamic 
ecosystems. All mucosal surfaces are directly exposed to the influence of environmental 
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factors of the outer world – they are all located at the edge of the outer world and the inner 
cosmos of the human body. The edge effect in ecology is the effect of the juxtaposition or 
placing side by side of contrasting environments on an ecosystem. The highest diversity of 
species and the strongest influence of the living creatures over habitats are found on edges 
[28]. The abrupt changes in the microbial community and/or the habitat may alter the 
balance and alter the the delicate equilibrium between the resident flora and human host – 
the so called homeostasis. The exogenous introduction of probiotic bacteria is unique as in 
terms of ecology it can be considered both as an abiotic environmental factor and a biotic 
factor of the living matter. The mucosal surfaces with their indigenous microbial 
communities are also unique as they are the combining the role of a habitat and a part of a 
living organism at the same time. The probiotic bacteria may interact with the resident flora 
and the microorganism and alter the homeostasis. The probiotic bacteria however interact 
with the mucosal immune system like any other bacteria.  
5. Intestinal homeostasis  
In healthy individuals there is a tolerance towards the resident flora. Because of that 
tolerance normally there is no aggressive cellular or humoral immune response towards the 
indigenous flora. The tolerance towards the intestinal flora and numerous dietary 
compounds is called oral tolerance. The oral and other types of antigen specific tolerance are 
dependent also on the mucosal permeability and the antigen clearance of lamina propria. This 
delicate equilibrium may be disturbed in various ways and lead to the development of an 
active disease. An example of such a disease is the IBD, in which the local and systemic 
immune response are aiming for the resident intestinal bacteria. The mucosal immune 
system in IBD is trying to permanently eliminate the intestinal microbiota, thus leading to 
the development of a chronic inflammation [29]. The mucosal immune system plays a key 
role for the maintenance of the mucosal homeostasis.  
6. Mucosal immune response  
The complex and well-set interaction between the probiotic bacteria, the indigenous flora 
and the mucosal surfaces are all possible because of the mucosal immune system and 
particularly the mucosa associated lymphoid tissues (MALTs). The MALTs are dispersed 
aggregates of nonencapsulated organized lymphoid tissue within the mucosa, which are 
associated with local immune responses at mucosal surfaces. Human MALTs consist mainly 
of the lymphoid structures within the GIT, urogenital tract, respiratory tract, nasal and oral 
cavities, the salivary and lacrimal glands, the inner ear, the synovia and the lactating 
mammary glands. The three major regions of MALTs are the gut-associated lymphoid tissue 
(GALT), bronchus-associated lymphoid tissue (BALT) and nasal-associated lymphoid tissue 
(NALT) however, conjunctiva-associated lymphoid tissue (CALT), lacrimal duct-associated 
(LDALT), larynx-associated (LALT) and salivary duct-associated lymphoid tissue (DALT) 
have also been described [30-34]. The organization of the MALTs is similar to that of lymph 
nodes with variable numbers of follicles (B-cell area), interfollicular areas (T-cell area), and 
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efferent lymphatics although afferent lymphatics are lacking. The overlying follicle 
associated epithelium is typically cuboidal with variable numbers of goblet cells and 
epithelial cells with either microvilli or numerous surface microfolds (M-cells). In addition, 
single lymphocytes can be observed within the epithelium, mucosa and lamina propria. All 
MALTs are morphologically similar although there are might be some differences in the 
percentage of T- and B-cells [35]. 
The GALT is typically organized into discrete lymphoid aggregates within the mucosa, 
submucosa and lamina propria of the small intestine called Peyer's patches (PP), the 
appendix, the mesenteric lymph nodes (MLN) and the solitary follicles. These aggregates 
are typically multiple lymphoid follicles with diffuse lymphatic tissue oriented towards the 
mucosa [36]. 
In the respiratory tract the NALT is the first site of contact for most airborne antigens and 
mostly presented by the tonsils and the adenoids at the entrance of the aerodigestive tract. 
The NALT bears certain similarities to the PP [34, 36]. 
The BALTs are organized aggregates of lymphocytes that are located within the bronchial 
submucosa. These aggregates are randomly distributed along the bronchial tract but are 
consistently present around the bifurcations of bronchi and bronchioli and always lie 
between an artery and a bronchus [34, 36]. 
The mucosal immune system has 3 main functions: 
- protects the mucosa against pathogenic microorganisms; 
- prevents the uptake of foreign proteins derived from ingested food, airborne matter 
and indigenous microbiota; 
- prevents the development of potentially detrimental immune response to these antigens 
in case they reach the body interior – i.e. oral tolerance in the gut. 
In contrast with the systemic immunity, which functions in a sterile milieu and often 
responds vigorously to “invaders”, the MALT protects the structures that are replete with 
foreign matter. The MALT must economically select appropriate effector mechanisms and 
regulate their intensity to avoid bystander tissue damage. 
All MALTs have two basic structures: organized and diffuse lymphoid tissue. In the GALT 
the organized tissues are mainly the PP, MLN and the appendix as the diffuse ones are the 
intraepithelial lymphocytes (IEL). [37, 38]. The other MALTs are similarly organized. 
The mucosal immune response has 2 phases: 
- inductive phase; 
- effector phase. 
Inductive phase 
The antigen uptake in the intestinal mucosa (especially particular antigens) occurs either 
through the specialized sampling system represented by the M-cells overlying the PP or 
across normal epithelium overlying the lamina propria. The M-cells may transport various 
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soluble antigens and even whole bacterial cells from the surface of the epithelium to the PP. 
Below the epithelium there are dendritic cells (DCs). The DCs perform phagocytosis of 
various antigens and present them to various immunocompetent cells in the mucosal 
immune system. The DCs may present the antigen to: 
- T-lymphocytes in the PP; 
- T-lymphocytes in the MLN – the antigen-loaded DCs may migrate from the PP through 
the afferent lymph vessels to the MLN and present the antigen there. 
The cells, which present antigens are called antigen presenting cells (APC). Some MHC class 
II (+) enterocytes may also act as APC. The M-cells, DCs, PP and the MLN perform the 
antigen presentation and recognition, thus fulfilling the so called inductive phase of the 
immune response [39-41]. 
Effector phase 
The diffuse lymphoid structures are mostly presented by the intraepithelial lymphocytes 
(IEL) – mature T-lymphocytes, and IgA producing plasma cells (activated B-cells). The T-
lymphocytes are divided to CD4+ (helper or inducer) and CD8+ (suppressor or cytotoxic). In 
most cases the APC present the antigens to naïve CD4+ cells and activate them (fig. 2). The 
Т-lymphocytes in lamina propria are predominantly CD4+, whereas the IEL are mostly 
CD8+. The activated CD4+ cells leave the organized lymphoid structures and using the 
lymphatic system reach the systemic circulation through the thoracic duct. The activated 
mucosal B-cells produce secretory IgA (sIgA), which is the principal mucosal 
immunoglobulin. Secretory IgA is a dimeric form of IgA and the two IgA molecules are 
binded by a joining chain. Secretory IgA inhibits the bacterial adhesion to the mucosa, 
carries out the lactoperoxidase and lactoferrin to the cell surface, takes part in the clearance 
of immune complexes and activates the alternative complement pathway. The IEL perform 
the effector phase of the immune response [37; 40].  
The inductive and efector immune response are interdependent and sometimes overlapping.  
The activated CD4+ may interact with other efector cells such as activated B-cells, CD8+ 
lymphocytes, etc. After priming, memory B- and T-cells migrate to other efector sites, 
followed by active proliferation, local induction of certain cytokines and production of 
secretory antibodies (IgA). The migration to other mucosal surfaces is called lymphocyte 
homing and it is possible because of the so called addressin receptors. By using the homing 
mechanism the lymphocytes sensitized in one part of the MALTs can reach all other 
mucosal sites [42]. About 80 % of the activated B-cells are found in the intestinal lamina 
propria. This is the main source of mucosal antibodies in MALTs [39; 43]. After priming, 
memory B- and T-cells migrate to effector sites, followed by active proliferation, local 
induction of certain cytokines and production of sIgA. 
The intestinal epithelium and the GALT play a crucial role in the maintenance of the oral 
tolerance – antigen specific tolerance to orally ingested food and bacterial antigens [44]. All 
mucosal epithelial layers are a part of the innate immunity and serve as a first line of 
defense against numerous exogenous factors. The epithelial cells in the gut form a reliable 
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and highly selective barrier between the intraluminal content and the body interior. The 
disruption of this barrier could lead to the development of an inflammatory response. This 
would be a result of the direct interaction between the GALT and the intraluminal antigens. 
This has been confirmed in animal models – the mice with genetically determined 
alterations of the intestinal permeability are developing intestinal inflammation [45, 46]. 
Normally there is a constant interaction between the intestinal epithelium and GALT thus 
making possible the existence of the oral tolerance [47]. 
There is a complex relationship between the intestinal immune system and the resident and 
transient intestinal microbiota and it is crucial for the epithelial cells and the mucosal immune 
system to distinguish between pathogenic and non-pathogenic agents. Intestinal epithelial 
cells and some enteroendocrine cells are capable of detecting bacterial antigens and initiating 
and regulating both innate and adaptive immune responses. Signals from bacteria can be 
transmitted to adjacent immune cells such as macrophages, dendritic cells and lymphocytes 
through molecules expressed on the epithelial cell surface – the so called pattern-
recognitioning receptors (PRRs). There are numerous PRRs: major histo-compatibility complex 
I and II molecules and Toll-like receptors (TLRs). TLRs alert the immune system to the 
presence of highly conserved microbial antigens called pathogen-associated molecular 
patterns (PAMPs). They are present on most microorganisms. Examples of PAMPs include 
lipopolysaccharides (LPS), peptidoglycan, flagellin, and microbial nucleic acids [4, 48-50]. This 
is exactly how probiotic bacteria interact with the mucosal immune system – by their PAMPs.  
There are at least ten types of human TLRs. In humans, TLRs are expressed in most tissues, 
including myelomonocytic cells, dendritic cells and endothelial and epithelial cells. Interaction 
of TLRs and PAMPs results in activation of a complex intracellular signaling cascade, up-
regulation of inflammatory genes, production of pro- and anti-inflammatory inflammatory 
cytokines and interferons, and recruitment of myeloid cells. It also stimulates expression of co-
stimulatory molecules required to induce an adaptive immune response of APC [4, 50]. The 
colonic epithelium expresses mostly TLR3 but also TLR4, TLR5, and TLR7 [51], while cervical 
and vaginal epithelial cells have a higher expression of TLR1, TLR2, TLR3, TLR5 and TLR6 [52]. 
TLR4 recognises LPS [53, 54], a constituent of the cell wall of Gram-negative bacteria, while 
TLR2 reacts with a wider spectrum of bacterial products such as lipoproteins, peptidoglycans 
and lipoteichoic acid found both in Gram-positive and Gram-negative bacteria [55, 56]. 
There is another family of membrane-bound receptors for detection of proteins and they are 
different from the TLRs. They are called NOD-like receptors or nucleotide-binding domain, 
leucine-rich repeat containing proteins (NLRs). The best characterised NLRs are NOD1 and 
NOD2. NRLs are located in the cytoplasm and are involved in the detection of bacterial 
PAMPs that enter the mammalian cell. NRLs are especially important in tissues where TLRs 
are expressed at low levels [57]. This is the case in the epithelial cells of the GIT where the 
cells are in constant contact with the microbiota, and the expression of TLRs must be down-
regulated in order to avoid over-stimulation and permanent activation. However, if these 
intestinal epithelial cells get infected with invasive bacteria or bacteria interacting directly 
with the plasma membrane, they will come into contact with NLRs and will activate some 
certain defense mechanisms [58]. NLRs are also involved in sensing other endogenous 
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warning signals which will result in the activation of inflammatory signalling pathways, 
such as nuclear factor-kappa B (NF-κB) and mitogen-activated protein kinases. Both NOD1 
and NOD2 recognise peptidoglycan moieties found in bacteria. NOD1 can sense 
peptidoglycan moieties containing meso-diaminopimelic acid, which primarily are 
associated to gram-negative bacteria. NOD2 senses the muramyl dipeptide motif that can be 
found in a wider range of bacteria, including numerous probiotic bacteria [59, 60]. The 
ability of NRLs to regulate, for example, nuclear factor-kappa B (NF-κB) signalling and 
interleukin-1-beta (IL-1β) production, indicates that they are important for the pathogenesis 
of inflammatory human diseases, such as IBD and especially Crohn’s disease. 
NOD2 are expressed mostly by DCs, granulocytes, macrophages and Paneth cells, as the 
TNFα and IFNγ up-regulate the expression of NOD2 in epithelial cells in intestinal crypts 
[59, 61, 62]. The overall expression of NOD1 and NOD2 increases in inflammation [63, 64].  
The microbiota alone can also predetermine the direction of this response with it’s PAMPs 
and their interaction with human PRRs. The NLRs and TLRs play a crucial role in the 
regulation of the inflammatory response towards indigenous and transient microbiota. The 
synthesis of various pro- and anti-inflammatory cytokines and/or activation of NF-kB may 
alter the direction of the immune response – from inflammation to anergy.  
The activation of the APC occurs after the binding of the PRRs with specific bacterial 
PAMPs. The types of PAMPs determine the selective activation of Th1, Th2, Th17 or Treg by 
the DCs (fig. 2).  
 
Figure 2. Interaction between the bacterial PAMPs, human PRRs, APCs, naïve CD4+ and activated 
CD4+ lymphocytes such as Th1, Th2, Th17 or Treg and their main cytokines.  
PAMP
PRR
Dendritic
cells
Naïve CD4+
Th1 TregTh2
IFNγ
TNFα
IL-10 
TGFβ
IL-4 
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Th17
IL-17 
IL-17F
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The activated CD4+ lymphocytes may be divided in 2 groups:  
- effector (Th1, Th2 and Th17); 
- regulatory (Treg) 
Effector CD4+ lymphocytes 
- Th1-lymphocytes: they secrete IL-2, TNFα, IFNγ and GM-CSF. These lymphocytes take 
part mostly in the cell-mediated immune response, the normal functions of the 
macrophages and the delayed hypersensitivity reactions;  
- Th2-lymphocytes: they secrete IL-4, IL-5, IL-6, IL-13 and mediate the humoral immune 
response, the synthesis of IgE and atopic disease;  
- Th17-lymphocytes – some authors link them with the development of numerous 
autoimmune diseases. Their activation and functions are not fully studies and 
understood but they differ from the Th1- and Th2-lymphocytes. Their activation is 
mediated by TGF-β, IL-6, IL-21 and IL-23 but suppressed by IFNγ and IL-4. The Th17-
lymphocytes secrete IL-17, IL-17F and IL-22. 
Regulatory CD4+ lymphocytes 
- Treg-lymphocytes: they secrete the anti-inflammatory IL-10 and TGFβ and mediate the 
intensity and the direction of the immune response. The animals with inborn deficiency 
of IL-10 and TGFβ develop acute enterocolitis with fatal consequences. This is a result 
of a paradoxical inflammatory response towards the resident intestinal flora [65-71]; 
There are parts of the indigenous microbiota that are less prone to induce inflammation, and 
there may even be bacterial genera with the ability to counteract inflammation. This 
seemingly inflammation-suppressing effect can be a result of different actions. The 
inflammation-suppressing fractions of the bacterial flora may be able to:  
- counteract some of the inflammation-aggravating bacteria, which will decrease the 
inflammatory response;  
- improve the barrier effect of the mucosa, which will inhibit the translocation of 
inflammation-inducing luminal contents into the body;  
- directly interact with pro-inflammatory processes and cascades of the immune system. 
All three actions may work simultaneously. Currently, the most studied inflammation-
suppressing indigenous bacteria are certain species/strains of Lactobacillus and Bifidobacterium, 
and those are also the main bacteria used in the production of probiotics [72]. 
The inflammation alone can be a consequence of allergic reactions, infectious diseases and 
autoimmune diseases such as rheumatoid arthritis, diabetes type 1, multiple sclerosis and 
Crohn’s disease, but a low-grade systemic inflammation also characterises the metabolic 
syndrome and the ageing human body. The long-term inflammation increases the risk for 
atherosclerosis, cancer, dementia and non-alcoholic fatty liver disease. Diabetes type 2 and 
obesity are also characterised by a low-grade inflammation but it is still unclear if the 
inflammation is the cause of the condition or just a result of it. The indigenous flora of the 
human body may trigger inflammation, and so favourable influence on the composition of 
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the indigenous microbiota can be a strategy to mitigate inflammation. The use of probiotic 
bacteria can affect the composition of the resident flora, but probiotics may also have more 
direct effects on the immune system and the permeability of the mucosa. The better the 
barrier effect of the mucosa the smaller the risk of translocation of pro-inflammatory 
components originating from the mucosal microbiota [72]. 
7. Probiotics and mucosal immune response in clinical practice  
The polarization of the immune response is the reason why the oral intake of probiotic 
bacteria has been proven to be effective in allergic inflammation – atopic dermatitis, vernal 
keratoconjunctivitis but also in inflammatory bowel disease [23, 24]; infectious and antibiotic 
induced diarrhea [19, 20], urogenital infections [21, 22], atopic disease [25, 26]. Probiotic-
induced immune modulation at mucosal sites distant from the gut supports the ‘hygiene 
theory’ of allergy development [73]. The ‘hygiene theory’ links the recent increase in the 
prevalence of allergic disease with modern western lifestyle, through altered patterns of gut 
colonisation characterised by a skewing towards an IFN-γ mucosal cytokine response [74]. 
In addition some authors suggest that probiotics may have a place as adjunctive treatment 
in H. pylori infections and possibly in their prophylaxis [75].  
Based on the clinical evidence we could assume that the effects of probiotic bacteria over the 
mucosal immune response may be divided into local and systemic. Indeed the efficacy of 
probiotic bacteria in atopic disease speaks of some systemic effect. Another perfect example 
for potential systemic efficacy are the immunological changes in breast milk, occurring after 
oral intake of Lactobacillus bulgaricus - “I. Bogdanov patent strain tumoronecroticance B-51” - 
ATCC 21815 [76]. According to the authors this is possible because of the functional entero-
mammaric link and the functional redistribution of activated lymphocytes from the gut to 
the mammary gland and vice versa. In addition to this Dalmasso et al. [77] reported a novel 
biological property of probiotic bacteria: their capacity to affect immune cell redistribution 
by improving the competence of lymphatic endothelial cells to trap T lymphocytes. 
The facilitation of oral tolerance and innocent bystander suppression by probiotic bacteria 
[78, 79] support the fact that particular probiotics not only drive protection against infection 
throughout the mucosal immune system, but also regulate the effector response. It is likely 
that different bacterial species operate through different mechanisms, indicating the 
importance of screening assays when identifying new isolates for clinical testing. It is 
suggested that a new term ‘immunobiotics’, identifying those bacteria that promote health 
through activation of the mucosal immune apparatus, is a necessary evolutionary step as the 
foundation of our knowledge expand regarding the host–parasite relationships and their 
outcomes, as they relate to health and disease. Recognition of bacteria that promote mucosal 
T-cell function as ‘immunobiotics’ moves probiotic biology forward by focusing on a 
mechanism of outcome, i.e. immunomodulation at distant mucosal sites. The human 
understanding of the interaction between the ‘immunobiotic’ bacteria with the MALTs 
increases further and particular effector molecules and their receptor targets are being 
identified. A new focus in biotherapy can be expected to evolve. It still remains to convert 
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predictable shifts in mucosal immunity into practical health gains for the benefits of 
immunobiotic therapy to be realised [74].  
8. Conclusion  
The Roman Emperor and Stoic Philosopher Marcus Aurelius has said “Constantly regard 
the universe as one living being, having one substance and one soul; and observe how all 
things have reference to one perception, the perception of this one living being; and how all 
things act with one movement; and how all things are the cooperating causes of all things 
which exist; observe too the continuous spinning of the thread and the contexture of the 
web.” [80]. Indeed the probiotics, the resident flora and the mucosal immune system are 
extremely strongly related and act as a single equilibrium and should always be 
investigated and described together. There is a long way to go until we fully understand 
and manage to control the interaction between the probiotic bacteria and the mucosal 
immune system. 
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